Skip Navigation


NDT Advance Access originally published online on October 12, 2005
Nephrology Dialysis Transplantation 2006 21(2):330-336; doi:10.1093/ndt/gfi177
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
21/2/330    most recent
gfi177v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (40)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Spandou, E.
Right arrow Articles by Tsakiris, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Spandou, E.
Right arrow Articles by Tsakiris, D.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2005]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org


Original Articles: Experimental Nephrology

Erythropoietin attenuates renal injury in experimental acute renal failure ischaemic/reperfusion model

Evangelia Spandou1, Ioannis Tsouchnikas2, George Karkavelas3, Evangelia Dounousi2, Constantina Simeonidou1, Olympia Guiba-Tziampiri1 and Dimitrios Tsakiris2

1 Department of Physiology, 3 Department of Pathology, Aristotle University of Thessaloniki and 2 Department of Nephrology, General Hospital of Veria, Greece

Correspondence and offprint requests to: D. Tsakiris, Department of Nephrology, General Hospital of Veria, Greece. Email: dimtsak{at}otenet.gr

Background. Erythropoietin (EPO), originally identified for its critical role in promoting erythrocyte survival and differentiation, has been shown to exert multiple paracrine/autocrine functions. Protective effects of EPO have been demonstrated in various tissues and experimental models of ischaemia-induced injury. In the present study, we investigated the effect of EPO on an in vivo rat model of renal ischaemia/reperfusion (I/R) injury and the possible mechanisms implicated in the EPO-mediated anti-apoptotic action.

Methods. Male Wistar rats, subjected to renal ischaemia for 45 min, were administered either saline or EPO (500 U/kg, i.p.) 20 min prior to I/R. A sham-operated group served as the control. At 48 h of reperfusion, the renal dysfunction and injury was assessed by measurement of serum biochemical markers (urea, creatinine) and histological grading. Apoptosis was assessed by the TUNEL method and morphological criteria. Expression of Bax and NF-{kappa}B (p65) was also evaluated.

Results. High levels of serum urea and creatinine were identified at 48 h after ischaemia. The EPO-treated group had significantly lower serum and creatinine levels. Semi-quantitative assessment of the histological lesions showed that rats subjected to I/R developed marked structural damage, whereas significantly less tubular damage was observed in the EPO-treated group. I/R caused an increase in TUNEL-positive cells that was accompanied by morphological evidence of apoptosis. In the EPO-treated rats only a few scattered TUNEL-positive cells were observed. Up-regulation of Bax in the tubular epithelial cells and increased expression of NF-{kappa}B was observed in the I/R-treated rats, while diminished expression of Bax and positive immunostaining of NF-{kappa}B was observed in the EPO-treated rats.

Conclusion. Administration of EPO as a single dose before the onset of ischaemia produced a significant reduction in tubular injury, which was accompanied by a marked amelioration of renal functional impairment. The cytoprotective action of EPO against I/R injury seems to be associated with its anti-apoptotic action. Moreover, transcription factor NF-{kappa}B is likely to play a pivotal role in the pathophysiology of I/R renal injury and might have a key role in EPO-mediated protective effects.

Keywords: acute renal failure; apoptosis; Bax; erythropoietin; ischaemia/reperfusion damage; NF-{kappa}B; p65


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Nephrol Dial TransplantHome page
N. D. Vaziri and X. J. Zhou
Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease
Nephrol. Dial. Transplant., April 1, 2009; 24(4): 1082 - 1088.
[Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
C. Contaldo, C. Meier, A. Elsherbiny, Y. Harder, O. Trentz, M. D. Menger, and G. A. Wanner
Human recombinant erythropoietin protects the striated muscle microcirculation of the dorsal skinfold from postischemic injury in mice
Am J Physiol Heart Circ Physiol, July 1, 2007; 293(1): H274 - H283.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
R. Zhande and A. Karsan
Erythropoietin promotes survival of primary human endothelial cells through PI3K-dependent, NF-{kappa}B-independent upregulation of Bcl-xL
Am J Physiol Heart Circ Physiol, May 1, 2007; 292(5): H2467 - H2474.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
P. Devarajan
Update on Mechanisms of Ischemic Acute Kidney Injury
J. Am. Soc. Nephrol., June 1, 2006; 17(6): 1503 - 1520.
[Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.